US Stock MarketDetailed Quotes

FHTX Foghorn Therapeutics

Watchlist
  • 6.710
  • +0.430+6.85%
Close Mar 28 16:00 ET
  • 6.680
  • -0.030-0.45%
Post 16:05 ET
285.62MMarket Cap-2867P/E (TTM)

About Foghorn Therapeutics Company

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Company Profile

SymbolFHTX
Company NameFoghorn Therapeutics
Listing Date10/23/2020
Issue Price16.00
Founded2015
CEOMr. Adrian Gottschalk
MarketNASDAQ
Employees116
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address500 Technology Square,Suite 700
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02139
Phone1-617-586-3100

Company Executives

  • Name
  • Position
  • Salary
  • Adrian Gottschalk
  • Chief Executive Officer and Director
  • 2.50M
  • Stephen J. DiPalma
  • Interim Chief Financial Officer
  • --
  • Michael J. LaCascia
  • Chief Legal Officer
  • 1.99M
  • Dr. Steven F. Bellon, PhD
  • Chief Scientific Officer
  • 1.19M
  • Fanny Cavalie
  • Chief Strategy and Business Operations Officer
  • --
  • Carlos Costa
  • Chief People Officer
  • --
  • Dr. Alfonso Quintas-Cardama
  • Chief Medical Officer
  • 1.84M
  • Dr. Douglas G. Cole, M.D.
  • Chairman of the Board
  • 184.57K
  • B. Lynne Parshall, Esq.,J.D.
  • Independent Director
  • 157.65K
  • Ian F. Smith
  • Independent Director
  • 141.57K
  • Dr. Thomas J. Lynch
  • Independent Director
  • 145.57K
  • Dr. Adam M. Koppel, M.D.,PhD
  • Independent Director
  • 153.07K
  • Dr. Scott Biller, PhD
  • Independent Director
  • 145.57K
  • Dr. Balkrishan Gill, PhD
  • Independent Director
  • 159.07K
  • Dr. Michael Mendelsohn, M.D.
  • Independent Director
  • 154.57K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg